Association Between a Functional Polymorphism Rs712 Within Let-7-binding Site and Risk of Papillary Thyroid Cancer

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2014 Sep 10

PMID 25201577

Citations 13

Authors

Hong Jin

Yundan Liang

Xunli Wang

Jingqiang Zhu

Ruifen Sun

Peng Chen

Xinwen Nie

Linbo Gao

Lin Zhang

Affiliations

Soon will be listed here.

Abstract

KRAS mutation is frequently detected in a series of cancers, including papillary thyroid cancer (PTC). Recently, a genetic variant of rs712 in the 3' untranslated region of the KRAS gene has been reported to be functional in the regulation of KRAS by disrupting complementary site of let-7 and miR-181. We aimed to investigate whether the polymorphism is a risk factor for PTC. We conducted an association study, including 252 PTC patients and 290 healthy controls. The KRAS rs712 polymorphism was genotyped by polymerase chain reaction-restriction fragment length polymorphism. Although no significant difference of the KRAS rs712 distribution was observed between cases and controls in overall analysis, stratification analysis showed that patients carrying the KRAS rs712TT genotype were less likely to develop stages T3 and T4 under a recessive genetic model (OR 0.26, 95% CI 0.08-0.82). These results supported the role of the KRAS rs712 polymorphism as a potential genetic biomarker for the extension of PTC. Further population-based association studies are of great value to confirm the results in diverse ethnicities.

Citing Articles

Association between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population.

Jin M, Lu F, Li X, Zhou W, Li S, Jiang Y J Clin Lab Anal. 2022; 37(1):e24806.

PMID: 36510353 PMC: 9833971. DOI: 10.1002/jcla.24806.

MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.

Papaioannou M, Chorti A, Chatzikyriakidou A, Giannoulis K, Bakkar S, Papavramidis T Front Oncol. 2022; 11:755097.

PMID: 35186709 PMC: 8851242. DOI: 10.3389/fonc.2021.755097.

Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival.

Wang D, Liu Q, Ren Y, Zhang Y, Wang X, Liu B Biosci Rep. 2021; 41(4).

PMID: 33825830 PMC: 8062955. DOI: 10.1042/BSR20204136.

Micromanaging aerobic respiration and glycolysis in cancer cells.

Orang A, Petersen J, McKinnon R, Michael M Mol Metab. 2019; 23:98-126.

PMID: 30837197 PMC: 6479761. DOI: 10.1016/j.molmet.2019.01.014.

Serum miRNAs as Biomarkers for the Diagnosis and Prognosis of Thyroid Cancer: A Comprehensive Review of the Literature.

Mahmoudian-Sani M, Mehri-Ghahfarrokhi A, Asadi-Samani M, Mobini G Eur Thyroid J. 2017; 6(4):171-177.

PMID: 28868257 PMC: 5567107. DOI: 10.1159/000468520.

References

Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

Park S, Sun J, Hong K, Kwak J, Kim E, Chung W . Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. Clin Chem Lab Med. 2013; 51(8):1673-80. DOI: 10.1515/cclm-2012-0375. View

Wogan G, Hecht S, Felton J, Conney A, Loeb L . Environmental and chemical carcinogenesis. Semin Cancer Biol. 2004; 14(6):473-86. DOI: 10.1016/j.semcancer.2004.06.010. View

Li Z, Pan X, Han B, Guo X, Zhang Z, Jia J . A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013; 34(5):3159-63. DOI: 10.1007/s13277-013-0885-x. View

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R . Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212. PMC: 3664492. DOI: 10.1155/2013/965212. View

Pan X, Sun R, Li Z, Guo X, Zhang Z, Qin H . A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol. 2013; 35(1):831-5. DOI: 10.1007/s13277-013-1114-3. View

Wang W, Chien Y, Wong Y, Lin Y, Lin J . Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma. Head Neck. 2011; 34(5):663-6. DOI: 10.1002/hed.21792. View

Pan X, Jia J, Guo X, Li Z, Zhang Z, Qin H . Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma. Fam Cancer. 2013; 13(1):93-7. DOI: 10.1007/s10689-013-9681-4. View

Irigaray P, Newby J, Clapp R, Hardell L, Howard V, Montagnier L . Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed Pharmacother. 2007; 61(10):640-58. DOI: 10.1016/j.biopha.2007.10.006. View

10.

Wang X, Shi Z, Wang X, Cao L, Wang Y, Zhang J . MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol. 2011; 138(4):573-84. DOI: 10.1007/s00432-011-1114-x. View

11.

Ho P, Barton A, Worthington J, Plant D, Griffiths C, Young H . Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis. 2007; 67(5):677-82. PMC: 2563264. DOI: 10.1136/ard.2007.071399. View

12.

Jung C, Little M, Lubin J, Brenner A, Wells Jr S, Sigurdson A . The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2013; 99(2):E276-85. PMC: 3913801. DOI: 10.1210/jc.2013-2503. View

13.

Castellano E, Sheridan C, Zaw Thin M, Nye E, Spencer-Dene B, Diefenbacher M . Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell. 2013; 24(5):617-30. PMC: 3826036. DOI: 10.1016/j.ccr.2013.09.012. View

14.

Dunn K, Espino P, Drobic B, He S, Davie J . The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol. 2005; 83(1):1-14. DOI: 10.1139/o04-121. View

15.

Zou M, Baitei E, Alzahrani A, BinHumaid F, Alkhafaji D, Al-Rijjal R . Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. 2014; 24(8):1256-66. PMC: 4106383. DOI: 10.1089/thy.2013.0610. View

16.

Ivanov V, Gorski A, Tsyb A, Maksioutov M, Tumanov K, Vlasov O . Radiation-epidemiological studies of thyroid cancer incidence among children and adolescents in the Bryansk oblast of Russia after the Chernobyl accident (1991-2001 follow-up period). Radiat Environ Biophys. 2006; 45(1):9-16. DOI: 10.1007/s00411-006-0039-2. View

17.

Kumar M, Lu J, Mercer K, Golub T, Jacks T . Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007; 39(5):673-7. DOI: 10.1038/ng2003. View

18.

Pazaitou-Panayiotou K, Iliadou P, Chrisoulidou A, Mitsakis P, Doumala E, Fotareli A . The increase in thyroid cancer incidence is not only due to papillary microcarcinomas: a 40-year study in 1 778 patients. Exp Clin Endocrinol Diabetes. 2013; 121(7):397-401. DOI: 10.1055/s-0033-1345125. View

19.

Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A . RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. DOI: 10.1016/j.cell.2005.01.014. View

20.

Jazdzewski K, Murray E, Franssila K, Jarzab B, Schoenberg D, de la Chapelle A . Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008; 105(20):7269-74. PMC: 2438239. DOI: 10.1073/pnas.0802682105. View